em 523 has been researched along with Autoimmune Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aoyama, N; Baba, S; Inui, A; Kasuga, M; Miyamoto, M; Morimoto, S; Nakajima, Y; Ohmoto, A; Okano, H; Ueno, N | 1 |
| Baba, T; Ishii, M; Kasai, F; Nakamura, T; Takebe, K | 1 |
1 trial(s) available for em 523 and Autoimmune Diabetes
| Article | Year |
|---|---|
Erythromycin derivative improves gastric emptying and insulin requirement in diabetic patients with gastroparesis.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Biomarkers; Diabetes Mellitus, Type 1; Erythromycin; Female; Gastric Emptying; Gastrointestinal Agents; Gastroparesis; Humans; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Male; Middle Aged; Postprandial Period; Time Factors | 1997 |
1 other study(ies) available for em 523 and Autoimmune Diabetes
| Article | Year |
|---|---|
EM523L, a nonpeptide motilin agonist, stimulates gastric emptying and pancreatic polypeptide secretion.
Topics: Adult; Aged; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Erythromycin; Evaluation Studies as Topic; Female; Gastric Emptying; Gastrointestinal Agents; Humans; Male; Middle Aged; Motilin; Pancreatic Polypeptide | 1996 |